Opioid and melanocortin receptors: do they have overlapping pharmacophores?

Biopolymers. 2008;90(3):433-8. doi: 10.1002/bip.20814.

Abstract

We have identified compound 1 as a novel ligand for opioid and melanocortin (MC) receptors, which is derived from the overlapping of a well known structure for the delta opioid receptor, 2,6-dimethyltyrosine (Dmt)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic), and a small molecule for the MC receptor, Tic-DPhe(p-Cl)-piperidin-4-yl-N-phenyl-propionamide. Ligand 1 showed that there is an overlapping pharmacophore between opioid and MC receptors through the Tic residue. The ligand displayed high biological activities at the delta opioid receptor (Ki = 0.38 nM in binding assay, EC(50) = 0.48 nM in GTP-gamma-S binding assay, IC(50) = 74 nM in MVD) as an agonist instead of an antagonist and showed selective binding affinity (IC(50) = 2.3 muM) at the MC-3 receptor rather than at the MC-5 receptor. A study of the structure-activity relationships demonstrated that the residues in positions 2, 3, and the C-terminus act as a pharmacophore for the MC receptors, and the residues in positions 1 and 2 act as a pharmacophore for the opioid receptors. Thus, this structural construct can be used to prepare chimeric structures with adjacent or overlapping pharmacophores for opioid and MC receptors.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Binding, Competitive
  • Cell Line
  • Cyclic AMP / analysis
  • Humans
  • Inhibitory Concentration 50
  • Kidney / cytology
  • Ligands
  • Radioligand Assay
  • Receptor, Melanocortin, Type 3 / agonists*
  • Receptor, Melanocortin, Type 3 / metabolism
  • Receptors, Opioid, delta / agonists*
  • Receptors, Opioid, delta / metabolism
  • Structure-Activity Relationship

Substances

  • Ligands
  • Receptor, Melanocortin, Type 3
  • Receptors, Opioid, delta
  • Cyclic AMP